A R Folsom1, W Tang1, L-C Weng1, N S Roetker1, M Cushman2,3, S Basu4, J S Pankow1. 1. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 2. Department of Medicine, University of Vermont, Burlington, VT, USA. 3. Department of Pathology, University of Vermont, Burlington, VT, USA. 4. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Abstract
UNLABELLED: ESSENTIALS: There is little prospective information on genetic risk scores to predict venous thromboembolism (VT). Community based cohort followed a median of 22.6 years for VT occurrence. A 5-SNP risk score identified whites at risk of VT, but not African Americans. The utility of genetic risk scores for VT is yet to be established. BACKGROUND: Case-control studies have created genetic risk scores of single nucleotide polymorphisms (SNPs) associated with venous thromboembolism (VTE) and documented their ability to predict VTE, but prospective data are lacking. OBJECTIVE: To test the ability of a genetic risk score to predict VTE incidence in a prospective study, particularly in African Americans. METHODS: We computed a previously proposed genetic risk score, based on five established VTE SNPs in the F5, F2, ABO, FGG, and F11 genes, in 9520 whites and 3049 African Americans initially free of VTE. We followed them a median of 22.6 years for VTE occurrence (n = 380 events in whites and n = 187 in African Americans). RESULTS: In whites, the five-SNP weighted genetic risk score ranged from 0 to 5.8, and VTE risk increased 1.41-fold (95% confidence interval [CI] 1.27-fold to 1.56-fold) per allele increment. In African Americans, the weighted genetic risk score ranged from 0 to 4.6 and the hazard ratio per risk allele was 1.14 (95% CI 0.94-1.38), with adjustment for 10 principal components of ancestry. The area under the receiver operating characteristic curve for 20-year prediction of VTE from the weighted genetic risk score was 0.59 (95% CI 0.56-0.63) in whites and 0.56 (95% CI 0.51-0.61) in African Americans. Adding non-genetic factors increased the area under the curve to 0.67 in whites and to 0.66 in African Americans. CONCLUSIONS: Higher values for a five-SNP genetic risk score helped identify white adults at risk of VTE. The genetic risk score did not identify future VTE occurrence in African Americans.
UNLABELLED: ESSENTIALS: There is little prospective information on genetic risk scores to predict venous thromboembolism (VT). Community based cohort followed a median of 22.6 years for VT occurrence. A 5-SNP risk score identified whites at risk of VT, but not African Americans. The utility of genetic risk scores for VT is yet to be established. BACKGROUND: Case-control studies have created genetic risk scores of single nucleotide polymorphisms (SNPs) associated with venous thromboembolism (VTE) and documented their ability to predict VTE, but prospective data are lacking. OBJECTIVE: To test the ability of a genetic risk score to predict VTE incidence in a prospective study, particularly in African Americans. METHODS: We computed a previously proposed genetic risk score, based on five established VTE SNPs in the F5, F2, ABO, FGG, and F11 genes, in 9520 whites and 3049 African Americans initially free of VTE. We followed them a median of 22.6 years for VTE occurrence (n = 380 events in whites and n = 187 in African Americans). RESULTS: In whites, the five-SNP weighted genetic risk score ranged from 0 to 5.8, and VTE risk increased 1.41-fold (95% confidence interval [CI] 1.27-fold to 1.56-fold) per allele increment. In African Americans, the weighted genetic risk score ranged from 0 to 4.6 and the hazard ratio per risk allele was 1.14 (95% CI 0.94-1.38), with adjustment for 10 principal components of ancestry. The area under the receiver operating characteristic curve for 20-year prediction of VTE from the weighted genetic risk score was 0.59 (95% CI 0.56-0.63) in whites and 0.56 (95% CI 0.51-0.61) in African Americans. Adding non-genetic factors increased the area under the curve to 0.67 in whites and to 0.66 in African Americans. CONCLUSIONS: Higher values for a five-SNP genetic risk score helped identify white adults at risk of VTE. The genetic risk score did not identify future VTE occurrence in African Americans.
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Keattiyoat Wattanakit; Pamela L Lutsey; Elizabeth J Bell; Heather Gornik; Mary Cushman; Susan R Heckbert; Wayne D Rosamond; Aaron R Folsom Journal: Thromb Haemost Date: 2012-07-10 Impact factor: 5.249
Authors: M Bruzelius; M Bottai; M Sabater-Lleal; R J Strawbridge; A Bergendal; A Silveira; A Sundström; H Kieler; A Hamsten; J Odeberg Journal: J Thromb Haemost Date: 2015-01-12 Impact factor: 5.824
Authors: Hugoline G de Haan; Irene D Bezemer; Carine J M Doggen; Saskia Le Cessie; Pieter H Reitsma; Andre R Arellano; Carmen H Tong; James J Devlin; Lance A Bare; Frits R Rosendaal; Carla Y Vossen Journal: Blood Date: 2012-05-14 Impact factor: 22.113
Authors: José Manuel Soria; Pierre-Emmanuel Morange; Joan Vila; Juan Carlos Souto; Manel Moyano; David-Alexandre Trégouët; José Mateo; Noémi Saut; Eduardo Salas; Roberto Elosua Journal: J Am Heart Assoc Date: 2014-10-23 Impact factor: 5.501
Authors: Brendan J Keating; Sam Tischfield; Sarah S Murray; Tushar Bhangale; Thomas S Price; Joseph T Glessner; Luana Galver; Jeffrey C Barrett; Struan F A Grant; Deborah N Farlow; Hareesh R Chandrupatla; Mark Hansen; Saad Ajmal; George J Papanicolaou; Yiran Guo; Mingyao Li; Stephanie Derohannessian; Paul I W de Bakker; Swneke D Bailey; Alexandre Montpetit; Andrew C Edmondson; Kent Taylor; Xiaowu Gai; Susanna S Wang; Myriam Fornage; Tamim Shaikh; Leif Groop; Michael Boehnke; Alistair S Hall; Andrew T Hattersley; Edward Frackelton; Nick Patterson; Charleston W K Chiang; Cecelia E Kim; Richard R Fabsitz; Willem Ouwehand; Alkes L Price; Patricia Munroe; Mark Caulfield; Thomas Drake; Eric Boerwinkle; David Reich; A Stephen Whitehead; Thomas P Cappola; Nilesh J Samani; A Jake Lusis; Eric Schadt; James G Wilson; Wolfgang Koenig; Mark I McCarthy; Sekar Kathiresan; Stacey B Gabriel; Hakon Hakonarson; Sonia S Anand; Muredach Reilly; James C Engert; Deborah A Nickerson; Daniel J Rader; Joel N Hirschhorn; Garret A Fitzgerald Journal: PLoS One Date: 2008-10-31 Impact factor: 3.240
Authors: Eun-Ju Lee; Daniel J Dykas; Andrew D Leavitt; Rodney M Camire; Eduard Ebberink; Pablo García de Frutos; Kavitha Gnanasambandan; Sean X Gu; James A Huntington; Steven R Lentz; Koen Mertens; Christopher R Parish; Alireza R Rezaie; Peter P Sayeski; Caroline Cromwell; Noffar Bar; Stephanie Halene; Natalia Neparidze; Terri L Parker; Adrienne J Burns; Anne Dumont; Xiaopan Yao; Cassius Iyad Ochoa Chaar; Jean M Connors; Allen E Bale; Alfred Ian Lee Journal: Blood Adv Date: 2017-06-29
Authors: Aaron R Folsom; Weihong Tang; Saonli Basu; Jeffrey R Misialek; David Couper; Susan R Heckbert; Mary Cushman Journal: Thromb Haemost Date: 2019-02-19 Impact factor: 5.249
Authors: Aaron R Folsom; Saonli Basu; Ching-Ping Hong; Susan R Heckbert; Pamela L Lutsey; Wayne D Rosamond; Mary Cushman Journal: Am J Med Date: 2019-04-04 Impact factor: 4.965
Authors: Aaron R Folsom; Pamela L Lutsey; Zachary C Pope; Oluwaseun E Fashanu; Jeffrey R Misialek; Mary Cushman; Erin D Michos Journal: Res Pract Thromb Haemost Date: 2019-12-13